Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
What is the impact of dynamic score reassessment for stroke and bleeding risk outcome prediction in atrial fibrillation patients?
2
Zitationen
4
Autoren
2025
Jahr
Abstract
INTRODUCTION: Dynamic reassessment of stroke and bleeding risks is a cornerstone of patient-centered care in atrial fibrillation (AF) management. Unlike traditional approaches that evaluate these risks only at diagnosis or at initiation of oral anticoagulation, current evidence emphasizes periodic reassessment due to the evolving nature of risks. AREAS COVERED: -VA) and HAS-BLED scores are associated with heightened risks of stroke and bleeding, underscoring the need for regular reassessment. Addressing modifiable risk factors such as hypertension, renal dysfunction, and concurrent medications is key to improving outcomes. Although several guidelines now recommend risk reassessment at least annually, optimal timing remains unclear. Evidence supports more frequent reassessments for low-risk stroke patients (every 4 months) and high-risk bleeding patients (within 4-6 weeks) to promptly identify changes requiring intervention. EXPERT OPINION: Despite its benefits, challenges remain regarding risk reassessment, including the lack of universally applicable intervals and the complexity of multidisciplinary evaluations. Future advancements in artificial intelligence tools are expected to enhance risk reassessment by enabling more precise, personalized, and dynamic patient management.
Ähnliche Arbeiten
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
2014 · 11.554 Zit.
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
2009 · 11.152 Zit.
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
2020 · 9.803 Zit.
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
2017 · 9.679 Zit.
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
2011 · 9.352 Zit.